Pathogenesis-Based Therapy With Repurposed Biologics for Monogenic Inflammatory Skin Disorders.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Secukinumab responses vary across the spectrum of congenital ichthyosis in adults.Archives of dermatological research · 2023
   Trial
2. Real-World Effectiveness of Secukinumab in Congenital Ichthyoses: A Retrospective Monocentric Case Series.Antibodies (Basel, Switzerland) · 2026
   Article
3. Advances in the treatment of autosomal recessive congenital ichthyosis, a look towards the repositioning of drugs.Frontiers in pharmacology · 2023
   Review
4. Treatments for Non-Syndromic Inherited Ichthyosis, Including Emergent Pathogenesis-Related Therapy.American journal of clinical dermatology · 2022
   Review
5. New developments in the molecular treatment of ichthyosis: review of the literature.Orphanet journal of rare diseases · 2022
   Review

Corrections and comments

• Comment on
  Secukinumab Therapy for Netherton Syndrome.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as